Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Kanazawa University Research: Possible Strategy for Cancer Treatment Found in Nuclear Transport Proteins


News provided by

Kanazawa University

17 Dec, 2019, 13:05 GMT

Share this article

Share toX

Share this article

Share toX

KANAZAWA, Japan, Dec. 17, 2019 /PRNewswire/ -- The nuclear import of proteins befalls through nuclear pore complexes (NPCs) and normally requires specific transport proteins. A type of a nuclear transport protein plays a key role in the proliferation and resistance to treatment of head and neck squamous carcinoma cells, report researchers at Kanazawa University. The results suggest that targeting specific nuclear transport systems may lead to possible therapeutic strategies.

Although less often the focus of cancer research, recent studies have hinted at the possible importance of a type of protein known as nuclear transport receptors. Now researchers at Kanazawa University and collaborating institutions in Japan and the US have identified a nuclear transport receptor protein that plays a key role in processes that sustain aggressive head and neck cancers, as well as some of the mechanisms behind these processes.

"Current gene expression network approaches commonly focus on TFs [transcription factors], biasing network-based discovery efforts away from potentially important non-TF proteins," point out Masaharu Hazawa and Richard Wong and their colleagues in the report of their latest results. Taking a different tack, they noted that although abnormalities in nuclear transport receptors and their significance in the progression of cancer were not yet understood, recent studies had identified the importance of a type of nuclear transport receptor named karyopherin-α  (KPNA)/importin-α in cell differentiation, whereby immature cells acquire the characteristics and functions of specific mature cell types. Tumors of non-differentiated cells are widely understood to be more aggressive.

Noting the role of KPNA in cell fate determination, Hazawa, Wong and colleagues re-analyzed the Cancer Genome Atlas, which identified  KPNA4 as most highly expressed subtype of KPNAs in head and neck squamous cancer cells (HNSCCs). Using a green fluorescent protein that had a nuclear localization signal, the researchers then investigated the role of KPNA4. They showed that while this green fluorescent protein would normally then localize in the nucleus, in HNSCCs where they had "knocked down" the gene expressing KPNA4 (so that the protein KPNA4 was not expressed) high levels of the green fluorescent protein remained in the cytoplasm instead. As well as the impact on nuclear transport of molecules with the nuclear localization signal, the researchers were also able to observe how silencing the KPNA4 expressing gene reduced the "cell proliferation, migration ability and resistance to radiation" in HNSCCs.

Further studies revealed not only the role of KPNA4 in repressing differentiation of epithelial cells, but also important transcription factors and signaling pathways controlled by KPNA4-dependent nuclear import systems. In their report the researchers conclude, "Taken together, these results indicate that targeting disease-specifically altered transport systems may serve as promising therapeutic strategies for cancer treatment."

Background

Head and neck squamous cell carcinoma

Squamous cell carcinomas are a non-melanoma type of skin cancer, which are the 5th most commonly occurring cancers worldwide. It is a disease that affects the squamous epithelium - flat cells found lining the skin and mucous membranes. Head and neck squamous cancer affects the mucous cells in the mouth, nose and throat.

Transcription factors

Transcription factors read and interpret the genetic code in cells. They bind to specific sequences of DNA and control the rate of transcription of that genetic code to messenger RNA, which then conveys that genetic information in the synthesis of new proteins. A number of cancer-suppressing transcription factors have already been identified.

Nuclear transport receptors

While small molecules can move relatively freely across the cell membrane, larger molecules such as proteins need nuclear transport receptors such as karyopherins/importins to enter or leave the cell. Karyopherins help macromolecules navigate the nuclear pore complexes that act as the gateway to the cell.

Differentiation

In a complex organism like a human most cells undergo several differentiations from the initial immature cell into more specialized mature cells that often have very different structures and functions. The process generally involves the activation of a dormant transcription factor.

Hazawa, Wong and colleagues noticed lower levels of KPNA4 where epithelial differentiation increased. Further tests identified that a particular protein regulated by KPNA4 is ras-responsive binding protein (RREB1), and that the Ras/MAPK signaling was affected. Previous work had already established the role of RREB1 in oncogenic Ras/MAPK signaling. Hazawa, Wong and colleagues found that KPNA4 activates a pathway based on Ras and MAPK proteins by mediating nuclear-transport of the Ras-responsive element-binding protein (RREB1). Furthermore, they identified MAPK-dependent processes that enhance transport activity of KPNA4, in what they describe as a "feed forward" process.

Reference

Masaharu Hazawa, Kie Sakai, Akiko Kobayashi, Hironori Yoshino, Yoshihiro Iga, Yuki Iwashima, Kee Siang Lim, Dominic Chih-Cheng Voon, Yan-Yi Jiang, Shin-ichi Horike, De-Chen Lin, Richard W. Wong. "Disease-specific alteration of karyopherin-α subtype establishes feed-forward oncogenic signaling in head and neck squamous cell carcinoma", Oncogene. Published online 10 December 2019.

DOI: https://doi.org/10.1038/s41388-019-1137-3

URL: https://www.nature.com/articles/s41388-019-1137-3

About Nano Life Science Institute (WPI-NanoLSI)

https://nanolsi.kanazawa-u.ac.jp/en/

Nano Life Science Institute (NanoLSI), Kanazawa University is a research center established in 2017 as part of the World Premier International Research Center Initiative of the Ministry of Education, Culture, Sports, Science and Technology. The objective of this initiative is to form world-tier research centers. NanoLSI combines the foremost knowledge of bio-scanning probe microscopy to establish 'nano-endoscopic techniques' to directly image, analyze, and manipulate biomolecules for insights into mechanisms governing life phenomena such as diseases.

About Kanazawa University

http://www.kanazawa-u.ac.jp/e/

As the leading comprehensive university on the Sea of Japan coast, Kanazawa University has contributed greatly to higher education and academic research in Japan since it was founded in 1949. The University has three colleges and 17 schools offering courses in subjects that include medicine, computer engineering, and humanities.

The University is located on the coast of the Sea of Japan in Kanazawa – a city rich in history and culture. The city of Kanazawa has a highly respected intellectual profile since the time of the fiefdom (1598-1867). Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Further information

Hiroe Yoneda
Vice Director of Public Affairs
WPI Nano Life Science Institute (WPI-NanoLSI)
Kanazawa University
Kakuma-machi, Kanazawa 920-1192, Japan
Email: nanolsi-office@adm.kanazawa-u.ac.jp 
Tel: +81-(76)-234-4550

Modal title

Also from this source

Kanazawa University Research: Visualizing the Mechanics of Hormone-Driven Gene Activation: Insights into Breast Cancer

Scientists at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University have captured real-time footage showing how a key hormone receptor...

Kanazawa University research: Decoding how cells communicate by high-speed imaging of molecular couriers

Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, demonstrates a novel approach for nanoscopic profiling of small extracellular...

More Releases From This Source

Explore

STEM (Science, Tech, Engineering, Math)

STEM (Science, Tech, Engineering, Math)

Computer & Electronics

Computer & Electronics

Education

Education

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.